HAVCR2 and melanoma: In combination with the reported efficacy, this suggests that TIM-3 blockade may reverse T-cell exhaustion and indicates the potential synergistic effect of concurrently targeting TIM-3 and PD-(L)1 in patients with melanoma who are immunotherapy-naïve, particularly before anti–PD-(L)1 resistance develops, i.e., in the first-line setting.